OCTAPHARMA

🇫🇷France

Country: 🇫🇷France

Ownership: -

Established: 1983-01-01

Employees: -

Market Cap: -

Website: https://www.octapharma.com/

Clinical Trials

Study to Evaluate the Efficacy, Tolerability and Safety of Octanorm in Patients With Primary Immunodeficiency Diseases

Phase 3

Completed

Conditions: Primary Immune Deficiency Disorder

Interventions: Biological: Octanorm

First Posted Date: 2019-06-17

Last Posted Date: 2020-03-10

Lead Sponsor: Octapharma

Target Recruit Count: 25

Registration Number: NCT03988426

Locations: 🇷🇺
State Medical University, Rostov, Russian Federation
🇷🇺
Pasteur Institute, Saint Petersburg, Russian Federation
🇷🇺
The State Research Center, Institute of Immunology of the Federal Medical-Biological Agency, Moscow, Russian Federation

and more 2 locations

Study to Monitor Subcutaneous Human Immunoglobulin Administered at Modified Dosing Regimens in Patients With Primary Immunodeficiency Diseases

Phase 3

Completed

Conditions: Primary Immune Deficiency Disorder

Interventions: Drug: CUTAQUIG

First Posted Date: 2019-05-06

Last Posted Date: 2023-11-07

Lead Sponsor: Octapharma

Target Recruit Count: 64

Registration Number: NCT03939533

Locations: 🇺🇸
Octapharma Research Site, Bellingham, Washington, United States

CLINICAL PHASE III STUDY TO MONITOR THE SAFETY, TOLERABILITY AND EFFICACY OF SUBCUTANEOUS HUMAN IMMUNOGLOBULIN (OCTANORM) IN PATIENTS WITH PRIMARY IMMUNODEFICIENCY DISEASES, INCLUDING (BUT NOT LIMITED TO) THOSE WHO HAVE COMPLETED THE SCGAM-01 TRIAL

Phase 3

Completed

Conditions: Primary Immunodeficiency

Interventions: Drug: Octanorm 16.5%

First Posted Date: 2019-04-08

Last Posted Date: 2020-10-27

Lead Sponsor: Octapharma

Target Recruit Count: 27

Registration Number: NCT03907241

Locations: 🇨🇦
Octapharma Research Site, Edmonton, Alberta, Canada

Study to Evaluate the Efficacy and Safety of PANZYGA in Pediatric Patients With Chronic Immune Thrombocytopenia (ITP)

Phase 4

Terminated

Conditions: Chronic Immune Thrombocytopenia

Interventions: Biological: Panzyga

First Posted Date: 2019-03-07

Last Posted Date: 2024-08-07

Lead Sponsor: Octapharma

Target Recruit Count: 6

Registration Number: NCT03866798

Locations: 🇺🇸
Octapharma Research Site, Houston, Texas, United States

Safety and Efficacy of Fibryga in Congenital Fibrinogen Deficiency

Recruiting

Conditions: Congenital Fibrinogen Deficiency

Interventions: Biological: Fibryga

First Posted Date: 2019-01-04

Last Posted Date: 2024-12-13

Lead Sponsor: Octapharma

Target Recruit Count: 25

Registration Number: NCT03793426

Locations: 🇩🇪
Gerinnungszentrum rhein-ruhr, Duisburg, Germany
🇨🇿
Fakultní nemocnice Ostrava, Ostrava, Czechia
🇩🇪
Gerinnungszentrum Hochtaunus, Hamburg, Germany

and more 1 locations

Efficacy, Safety & Utilisation of Nuwiq, Octanate and Wilate in Previously Untreated & Minimally Treated Haemophilia a Patients

Recruiting

Conditions: Haemophilia a

First Posted Date: 2018-10-04

Last Posted Date: 2024-11-04

Lead Sponsor: Octapharma

Target Recruit Count: 200

Registration Number: NCT03695978

Locations: 🇫🇷
CHRU Hopital Nord, Secretariat de pediatre, bat E niv +3, Saint-Priest-en-Jarez, France
🇮🇹
Azienda Ospedaliera-Universitaria Policlinico "Vittorio Emanuele", Centro di Riferimento Regionale per la Prevenzione, Diagnosi e Cura delle Malattie Rare della Coagulazione nel Bambino e neel'Adulto. U.O.C Ematologia con trapianto di Midollo Osseo, Catania, Italy
🇺🇸
Cure 4 The Kids Foundation Children's Specialty Center, Las Vegas, Nevada, United States

and more 39 locations

Study Evaluating Efficacy and Safety of Octanorm in Patients With Dermatomyositis

Phase 3

Terminated

Conditions: Dermatomyositis

Interventions: Drug: Octanorm
Other: Placebo

First Posted Date: 2018-09-27

Last Posted Date: 2021-04-23

Lead Sponsor: Octapharma

Target Recruit Count: 1

Registration Number: NCT03686969

Locations: 🇷🇺
I.M. SECHENOV FIRST MOSCOW STATE MEDICAL UNIVERSITY Rheumatology Department Of, Clinici Of Nephrology, Moscow, Russian Federation

Trial Assessing Safety and Efficacy of Gammanorm® in Autoimmune Diseases

Terminated

Conditions: Autoimmune Diseases

Interventions: Drug: Gammanorm

First Posted Date: 2018-09-04

Last Posted Date: 2021-03-10

Lead Sponsor: Octapharma

Target Recruit Count: 60

Registration Number: NCT03656640

Locations: 🇲🇶
CHU de la Martinique- Hopital Pierre Zobda Quitman, Fort-de-France, Martinique
🇫🇷
Chu de Rouen - Bois Guillaume, Rouen, France
🇫🇷
APHP - Pitie Salpetriere, Paris, France

Study Comparing Weekly Intravenous Administration of OctaAlpha1 With a Marketed Preparation Glassia® in Subjects With Alpha-1-antitrypsin Deficiency

Phase 2

Withdrawn

Conditions: Alpha 1-Antitrypsin Deficiency

Interventions: Drug: Glassia
Drug: OctaAlpha1

First Posted Date: 2017-12-28

Last Posted Date: 2018-04-10

Lead Sponsor: Octapharma

Registration Number: NCT03385395

Pharmacokinetics, Efficacy, Safety, and Immunogenicity of Wilate in Previously Treated Paediatric Patients With Severe Haemophilia A

Phase 3

Completed

Conditions: Severe Hemophilia A

Interventions: Drug: Wilate

First Posted Date: 2017-12-18

Last Posted Date: 2021-01-19

Lead Sponsor: Octapharma

Target Recruit Count: 11

Registration Number: NCT03376516

Locations: 🇷🇺
Kirov SSC Hematology and Transfusiology, Kirov, Russian Federation
🇺🇦
"National Children's Specialized Clinic "OKHMATDYT", Kyiv, Ukraine
🇺🇦
"Western Ukrainian Specialized Children's Medical Center", Lviv, Ukraine

Home Terms & Conditions Privacy Policy